bms-936559
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01455103)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297702 ↗
Also known as
- bms-936559
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02576457 | Phase 1 | Dec 2, 2015 | Bristol-Myers Squibb |
| NCT02028403 | Phase 1 | Jun 1, 2014 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT01452334 | Phase 1 | Nov 1, 2011 | Bristol-Myers Squibb |
| NCT01455103 | Phase 1 | Nov 1, 2011 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2014 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1